TheBodyPro: Expert analysis from Benjamin Young, M.D., Ph.D.
Long-acting, injectable antiretroviral therapy (LA-ART) is still only indicated in the U.S. for a narrow subset of optimal patients. But what about the vast swath of people who struggle to maintain a daily oral regimen and wish they had a monthly option? Newly published results from a major study underscore just how valuable LA-ART can be for this population — while also helping us to pause and appreciate that making LA-ART available to them is only a part of what these patients truly need.
Read the full analysis here.
Source : TheBodyPro
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.